About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Texture Features and PDL1 in CT-PET 18 FDG

NCT04309422·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Hospital, Montpellier

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

adult patient ;
first CT-PET 18 FDG realized for the inital staging ;
absence of previous treatment for a thoracic neoplasm ;
biopsy realized on the primitive site or local drainage lymphadenopathy ;
primitive site viewable with morphological imagery ;
availability of evaluation of PDL1's overexpression ;

You may not be if

\- Refusal to participate in this research

The record

StatusCompleted

PhaseNo phase

Taking part84

StartedApr 2018

UpdatedMar 18, 2020

Conditions

Non Small Cell Lung Cancer

Where1

Uh Montpellier
Montpellier, France

Clareo Health | Texture Features and PDL1 in CT-PET 18 FDG